Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Price Target of $3.90 According to Analysts

Posted by Brian Himes on Nov 6th, 2026

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $3.90.

A number of equities research analysts have recently commented on AKBA shares. HC Wainwright reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research report on Thursday, August 6th. Leerink Partners downgraded Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 target price on the stock. in a research report on Friday, August 7th. Westpark Capital began coverage on Akebia Therapeutics in a research note on Tuesday, September 8th. They issued a “buy” rating and a $4.50 price target on the stock. BTIG Research restated a “buy” rating and issued a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Finally, Weiss Ratings downgraded shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd.

Get Our Latest Analysis on AKBA

Akebia Therapeutics Stock Performance

Shares of AKBA stock opened at $0.43 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.35 and a current ratio of 1.43. Akebia Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.11. The business has a fifty day simple moving average of $0.82 and a 200-day simple moving average of $1.13.

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%. The company had revenue of $36.90 million during the quarter, compared to analysts’ expectations of $46.94 million. On average, analysts predict that Akebia Therapeutics will post -0.14 earnings per share for the current year.

Institutional Trading of Akebia Therapeutics

Institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. increased its position in shares of Akebia Therapeutics by 33.7% in the third quarter. Alps Advisors Inc. now owns 364,094 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 91,832 shares in the last quarter. State of Wyoming lifted its position in shares of Akebia Therapeutics by 1,090.7% during the third quarter. State of Wyoming now owns 192,008 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 175,883 shares in the last quarter. PFG Private Wealth Management LLC purchased a new position in shares of Akebia Therapeutics in the third quarter valued at $34,000. Headlands Technologies LLC boosted its stake in shares of Akebia Therapeutics by 60.3% in the second quarter. Headlands Technologies LLC now owns 77,992 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 29,334 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in shares of Akebia Therapeutics in the second quarter valued at $46,000. 33.92% of the stock is owned by hedge funds and other institutional investors.

Akebia Therapeutics Company Profile

(Get Free Report)

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.